Adenosine is a potent vasodilator used extensively to study the coronary circulation of animals. Its use in humans, however, has been hampered by lack of knowledge about its effects on the human coronary circulation and by concern about its safety. We investigated in humans the effects of adenosine, administered by intracoronary bolus (2-16 jig), intracoronary infusion (10-240 ,ug/min), or intravenous infusion (35-140 pg/kg/min) on coronary and systemic hemodynamics and the electrocardiogram. Coronary blood flow velocity (CBFV) was measured with a 3F coronary Doppler catheter. The maximal CBFV was determined with intracoronary papaverine (4.5±0.2. resting CBFV). In normal left coronary arteries (n=20), 16-pg boluses of adenosine caused coronary hyperemia similar to that caused by papaverine (4.6±0.7 * resting CBFV). In the right coronary artery (n=5), 12-,ug boluses caused maximal hyperemia (4.4± 1.0 * resting CBFV). Intracoronary boluses caused a small, brief decrease in arterial pressure (similar to that caused by papaverine) and no changes in heart rate or in the electrocardiogram. The duration of hyperemia was much shorter after adenosine than after papaverine administration. Intracoronary infusions of 80 ,g/min or more into the left coronary artery (n=6) also caused maximal hyperemia (4.4±0.1. resting CBFV), and doses up to 240 pg/min caused a minimal decrease in arterial pressure (-6±2 mm Hg) and no significant change in heart rate or in electrocardiographic variables. Intravenous infusions in normal patients (n=25) at 140 ,ug/kg/min caused coronary vasodilation similar to that caused by papaverine in 84% of patients (4.4±0.9 -resting CBFV). At submaximal infusion rates, however, CBFV often fluctuated widely. During the 140-,ug/kg/min infusion, arterial pressure decreased 6±7 mm Hg, and heart rate increased 24± 14 beats/min. One patient developed 1 cycle of 2:1 atrioventricular block, but otherwise, the electrocardiogram did not change. In eight patients with microvascular vasodilator dysfunction (ACBFV, <3.5 peak/resting velocity after a maximally vasodilating dose of intracoronary papaverine), the dose-response characteristics to intracoronary boluses and intravenous infusions of adenosine were similar to those found in normal patients. These studies suggest that maximal coronary vasodilation can be achieved safely with intracoronary adenosine administration and that intravenous infusions at a rate of 140 ,ug/kg/min cause near-maximal coronary hyperemia in most patients. (Circulation 1990;82:1595-1606 M aany studies of the coronary circulation require the use of drugs that can safely and reliably produce maximal coronary hyperemia of brief duration (for example, for measurement of coronary flow reserve, thallium-201 scintigraphy, and echocardiographic imaging).1-6 An ideal agent for these studies would cause maximal 
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Since the identification of nucleoside adenosine in the myocardium in 1929, many investigators have shown that it is synthesized in the myocardium and that interstitial adenosine concentration rises in response to increased metabolic oxygen requirements and ischemia.15-17 Although the physiological role of adenosine in regulating coronary blood flow is uncertain, exogenously administered adenosine is known to cause profound microvascular coronary dilation mediated by an adenosine receptor on the cell membrane of resistance vessel myocytes.18 Three properties of adenosine have led to its extensive use in animal studies designed to assess the effects of pathological states (hypertrophy, infarction, and cardiomyopathy) on minimal total coronary resistance. First, intravenous or intracoronary adenosine can reliably increase coronary conductance to maximal levels (that is, at or exceeding that produced by transient ischemia).10 Second, the duration of action of adenosine is very brief (5-30 seconds).17,19 Third, at high doses, adenosine produces transmural vasodilation. 20 Despite the widespread use of adenosine in animal studies, concern over adenosine-induced hypotension and heart block have hampered its use in humans. In dogs, intravenous doses sufficient to produce maximal coronary dilation also results in a significant fall in systemic arterial blood pressure.20 In addition, large doses of adenosine increase the refractory period of the sinoatrial and atrioventricular nodes and can result in heart block.21 A preliminary study using intracoronary adenosine in humans revealed a strikingly high incidence of adenosineinduced conduction block in the atrioventricular node. 22 The purpose of this study was to examine the dose-response kinetics of intravenous and intracoronary adenosine administration in humans.
Methods

Patient Selection
Thirty-nine patients undergoing coronary angiography for the diagnosis of a chest pain syndrome were studied. Two groups were studied. Intracoronary papaverine. After measurement of resting blood flow velocity, 6-12 mg papaverine (2 mg/ml 0.9% saline) was injected through the guide catheter into the coronary ostium, and the resultant increase in coronary blood flow velocity was recorded. To confirm that any dose of papaverine produced maximal coronary hyperemia, an addi-tional, larger dose was administered, and the resultant hyperemic response was recorded. Blood flow velocity was allowed to return to baseline levels between doses of papaverine. In 31 patients, the left coronary artery was studied. In the remaining eight patients, blood flow velocity was measured in the right coronary artery. The mean dose needed to produce maximal hyperemia was 10±2 mg.
Intracoronary boluses of adenosine. After coronary blood flow velocity had returned to basal levels, sequentially greater boluses of adenosine (2 ,gg/ml 0.9% saline, MedCo Research, Los Angeles) were injected through the guide catheter into the coronary ostium. In Data Analysis Intracoronary bolus studies. The maximal change in coronary blood flow velocity after a bolus of intracoronary papaverine or adenosine was expressed as the ratio of the maximal coronary blood flow velocity (after adenosine or papaverine administration) to the resting blood flow velocity (ACBFV). An index of the change in total coronary resistance (ATCRI) was calculated as the quotient of the peak hyperemic coronary blood flow velocity (kHz) shift divided by mean arterial pressure at peak hyperemia (in mm Hg) and (coronary blood flow velocity at rest divided by arterial pressure at rest).
The time course of the increase in coronary blood flow velocity after intracoronary vasodilator administration was characterized by three parameters. T90%
was defined as the time from the onset of injection to until coronary blood flow velocity reached 90% of the eventual maximal increase in velocity. Tm. dur was defined as the time during which blood flow velocity remained 90% or more of the peak flow velocity. T10%
was defined as the time from the onset of injection until flow velocity returned to within 10% of basal flow velocity.
Intracoronary infusion studies. The change in coronary blood flow velocity during each infusion was calculated as the quotient of the mean coronary blood flow velocity (kHz shift) from 110-120 seconds after the onset of the infusion (when a steady state had been achieved) and the basal coronary blood flow velocity. The changes in heart rate, arterial pressure, and an index of total coronary resistance (calculated as described above) were also assessed during the last 10 seconds of the infusion.
Intravenous infusion studies. The change in coronary blood flow velocity during each intravenous adenosine infusion was calculated as the quotient of the peak mean blood flow velocity (kHz shift) during the infusion and the basal blood flow velocity. In cases where the blood flow velocity had marked cyclical variation during adenosine infusion (that is, .20% fluctuation in total coronary resistance index at "steady state"), the existence of cyclic variations was noted, but the average change in blood flow velocity during the last 10 seconds of the infusion was recorded. The changes in heart rate, arterial pressure, and total coronary resistance were also assessed at the peak change in coronary blood flow velocity.
Statistical Analysis
Differences between group means were tested by analysis of variance. Paired differences were analyzed with a paired t test. Linear correlation was assessed with the least-squares method. Except where noted, all data are expressed as mean ± SD. Statistical significance was defined as a p value of 0.05 or less.
Results
Intracoronary Adenosine Boluses
Coronary blood flow velocity and resistance. Intracoronary boluses of adenosine produced a dose- The onset of maximal hyperemia (Tg9%) was more rapid after adenosine compared with that of papaverine. The duration of maximal hyperemia (Tmax dur) and time required for blood flow velocity to return to basal levels (T10%) increased with the dose of adenosine, but at any dose, both parameters were much shorter than those observed after intracoronary papaverine administration (Tables 1 and 2 arterial pressure after an 8-, 12-, or 16-,ug bolus was similar in magnitude to that found after intracoronary papaverine (mean dose, 10±2 mg). The fall in arterial pressure for an equal dose of adenosine was significantly greater when adenosine was injected into the right compared with the left coronary artery (Tables 1 and 2 ). The fall in arterial pressure after a 12-,ug bolus into the right coronary artery was not different from that after a 16-,g bolus into the left coronary artery, suggesting that doses with similar vasodilator effects caused similar changes in arterial pressure.
There was no significant change in heart rate after any dose of adenosine was injected into the right or left coronary artery. Intracoronary papaverine, however, caused a small, but significant, increase in heart (Table 3 ). All patients had increased blood flow velocity maximally (equivalent to that achieved with intracoronary papaverine) at infusion rates of 80 ,ug/min or less. Cyclic variations in blood flow velocity at submaximal infusion rates (see below) were not observed. The time from the onset of a 240-,ug/kg/min infusion until blood flow velocity was within 90% of the eventual peak was 47± 31 seconds. The time from the offset of the infusion until blood flow velocity was within 10% of basal values was 143+75 seconds.
Systemic hemodynamics. The heart rate was not significantly changed during the intracoronary infusions (Table 3) , even at infusion rates fourfold higher than those needed to cause maximal hyperemia (that is, 240 ,ug/min). Mean arterial blood pressure fell minimally, but significantly, during the 120-and 240-,gg/min infusions (mean change, -9±7 and -6±5 mm Hg, respectively).
Electrocardiographic changes. None of the electrocardiographic intervals changed during the intracoronary infusions of adenosine (Table 3) .
Intravenous Adenosine Infusion
Coronary blood flow velocity and resistance. Intravenous adenosine infusions resulted in a dosedependent increase in coronary blood flow velocity and decrease in total coronary resistance such that minimal total coronary resistance during the 140-jttg/ kg/min infusion was not significantly different from that elicited by papaverine (Table 4 , Figures 4 and 5) . In 11 normal patients (44%), an infusion rate of 100 ,ug/kg/min was sufficient to decrease total coronary resistance to within 10% of the minimal resistance after papaverine. In 10 of the remaining patients, an infusion rate of 140 ,ug/kg/min was needed to reduce resistance to within 10% of the papaverine-induced minimal resistance. Four patients, however, failed to achieve maximal vasodilation with an infusion rate of 140 1g/kg/min. In two, the 140-,ug/kg/min infusion reduced coronary resistance to 0.22-0.27 * resting resistance, but that was at least 10-30% greater than the minimal resistance caused by papaverine. In the remaining two, the infusion failed even to decrease coronary resistance to within 30% of the papaverineinduced minimal resistance. An increase in the infusion rate to 180-200 ,ug/kg/min failed to elicit any greater vasodilation. Hence, 84% of normal patients achieved maximal vasodilation at an infusion rate of 140 j.g/kg/min or less, 92% achieved near-maximal hyperemia, but 8% failed to develop hyperemia within 30% of that produced by papaverine. The dose-response relation was similar in a smaller group of patients with microvascular dysfunction.
At the lower infusion rates (70-100 yg/kg/min), coronary blood flow velocity often rose and fell in a cyclic pattern with a cycle length of about 30 seconds (Table 4, Figure 5 ). Two factors suggest that the cyclic variation in coronary conductance resulted from a cyclical variation in adenosine concentration in the blood perfusing the myocardium. First, when the coronary infusion rate was increased, hyperemia became sustained at the maximal level. Second, intracoronary bolus injections of adenosine at the time when coronary blood flow velocity had receded, resulted in a prompt increase in blood flow velocity. To further investigate the mechanism of this cyclic phenomena, we changed the infusion site from the peripheral vein to the femoral vein in three patients; the pattern did not change. There was no difference 
Potential Methodological Problems
There are several potential problems that should be considered when interpreting these data. Those related to measurement of coronary blood flow using a coronary Doppler catheter have been discussed in detail elsewhere.8 Of importance, all patients received intracoronary nitroglycerin to maximally dilate the vessel containing the Doppler catheter, and the guide catheter was withdrawn from the coronary ostium at peak hyperemia to ensure that maximal blood flow into the ostium was not impeded by the catheter.
A second potential problem is that we purposely did not control heart rate, arterial pressure, or left ventricular preload during these studies. In this study, we administered two drugs that change both arterial pressure and heart rate. We have recently shown in humans that increases in heart rate augment resting coronary blood flow without altering maximal hyperemic flow (reducing the peaklresting velocity ratio), whereas increases in arterial blood pressure cause proportionately equal increases in resting and hyperemic blood flow (preserving the peak/resting velocity ratio). required to cause maximal hyperemia may be significantly higher in patients with increased ventricular mass. Our limited studies in patients with microvascular dysfunction, however, failed to show any difference in the dose-response relation. Further studies will be required to define the vasodilator properties and safety of adenosine in humans with other cardiovascular disease (for example, sinoatrial or atrioventricular node disease, baroreceptor dysfunction, or ventricular hypertrophy).
Comparison With Previous Studies
Aside from an assessment of the dose-response characteristics of adenosine in humans, the two major findings of this study are an apparent species difference in the response to intravenous adenosine and an observation in humans that coronary resistance fluctuates widely at submaximal adenosine infusion rates. Rembert et a120 reported that an intravenous adenosine infusion rate of 1,000 ,ug/kg/ min was required to elicit maximal transmural coronary hyperemia. Lesser infusion rates caused maximal subendocardial vasodilation, but conductance of blood to the subepicardial muscle was not maximal. In humans, however, we found that an infusion of adenosine at only 140 gg/kg/min decreased coronary resistance to within 14+8% of that induced by papaverine, with a small concomitant increase in arterial blood pressure and a moderate increase in heart rate. These data suggest that humans are more sensitive than are dogs to the vasodilator properties of adenosine or that the rate of adenosine elimination is slower in humans.
Although the species differences in response to adenosine are clear, it should be emphasized that an adenosine infusion of 140 gg/kg/min in humans may not have produced absolutely maximal vasodilation in the subepicardial myocardium in all patients. In 16%, the minimal resistance during the 140-gg/kg/ min infusion was more than 10% greater than that produced by papaverine. Similar intraspecies differences in adenosine responsiveness have been reported in dogs.26 Although higher infusion rates may possibly cause maximal hyperemia, the safety of higher doses needs to be established. Our experience demonstrated that an infusion rate of 140 gg/kg/min significantly increased the heart rate; higher infusion rates may not be well tolerated in a significant fraction of patients.
We also found that intravenous infusion rates just less than those required to produce a maximal fall in coronary resistance frequently cause a characteristic pattern of widely fluctuating coronary resistance (that is, >20%) that has not been reported in prior studies in animals. The pattern was not affected by changes in the site or concentration of infusion and disappeared when the infusion rate was increased.
We believe that this occurred in humans and not in dogs because of the short half-life of adenosine and the longer circulation time in humans that weigh 70-100 kg compared with that in dogs that weigh 20-30 kg. Initially, the adenosine was infused into a vein with relatively slow blood flow, resulting in a high concentration of adenosine. When the adenosine reached the systemic circulation, vasodilation and an increase in vein blood flow occurred. The adenosine, continuously administered at the same infusion rate, was then diluted to a lower concentration. Simultaneously, the adenosine administered at the beginning of the infusion was metabolized. The lower plasma concentration of adenosine that then reached the coronary and systemic vasculature produced less vasodilation, allowing blood flow to decrease. As venous blood flow returned to the basal level, the plasma concentration of adenosine again rose and the cycle started again. If the circulation time was faster (as in the smaller dog), then more adenosine would survive more than one circulation (particularly if the elimination rate was slower), and cyclic variations would not occur. Similarly, if the infusion rate was increased, the trough level of adenosine would still be sufficient to cause maximal vasodilation.
Two factors support this explanation. Additional intracoronary adenosine, given when blood flow velocity was decreasing, resulted in a prompt rise in flow velocity, suggesting that the fall in blood flow resulted from a lower arterial concentration of adenosine rather than decreased local effect. Second, there is inferential evidence that a fraction of the adenosine was metabolized as it passed from the venous infusion site to the myocardium. Under normal circumstances, the left coronary artery receives 2-3% of the total cardiac output. Unless there was significant metabolism, one would anticipate that the intracoronary dose needed to cause maximal hyperemia would be 2-3% of the intravenous dose. We found, however, that the intracoronary infusion rate needed to cause maximal hyperemia was less than 1% of the intravenous dose, suggesting that some adenosine was metabolized before it arrived in the coronary artery.
An additional explanation for cyclic hyperemia is that adenosine, at low doses, caused platelet activation that secondarily reduced hyperemic blood flow. This is unlikely because in vitro studies have shown that adenosine reduces platelet aggregation.27 Furthermore, animal models in which platelet-mediated cyclic flow variation has been observed use severe coronary stenoses, cause cyclic reductions of resting coronary blood flow (not hyperemic flow), and tend to have a much longer periodicity. 28, 29 In addition, pretreatment with aspirin, a drug that abolishes cyclic variations in animal models, failed to alter the incidence of flow variations in humans.
The clinical importance of the phenomenon is that, in contrast to dogs, submaximal doses of adenosine in humans may not cause sustained submaximal hyperemia. Consequently, if adenosine is used as an adjuvant to 2Okl1 scintigraphy, injection of thallium at the low ebb of coronary hyperemia may result in falsely normal findings. 30 Fortunately, the vast majority of patients achieved sustained maximal coronary hyperemia at an infusion rate of 140 ,g/kg/min. These studies suggest that an infusion rate of 140 ,ug/kg/ min should be used unless the patient develops hypotension or marked tachycardia at a lower dose.
Prior investigators have reported that in humans much larger doses of intracoronary adenosine are required to cause maximal coronary vasodilation. Zijlstra et a122 found that intracoronary boluses of 50-800 jig were required to produce maximal coronary hyperemia. 22 The magnitude of maximal coronary blood flow obtained with papaverine or adenosine, however, was very low (1.6±0.3 peak/resting coronary blood flow velocity), suggesting that many of the patients studied had microvascular disease or other illnesses that may have altered the response to adenosine. They also reported a high incidence of transient heart block that may have been related to the large dose of adenosine administered concurrently with agents that depress atrioventricular and sinoatrial node function (for example, diltiazem, ,B-adrenergic receptor antagonists). Other investigators31-34 have also studied the effects of adenosine on the peripheral or coronary circulation of humans. The lack of dose-response data or problems in measurement techniques make the interpretation of their findings difficult. Potential Uses ofAdenosine in Humans We studied the effects of adenosine on the coronary circulation of humans for two reasons: one related to clinical application and the other related to basic study of the coronary circulation. It was recently suggested that intravenous adenosine infusions may supplant dipyridamole in providing coronary vasodilation in conjunction with 20`T1 scintigraphic studies. 30 The ultrashort half-life of adenosine compared with that of dipyridamole may lessen the risk of prolonged coronary ischemia due to vasodilator-induced coronary "steal" and reduce the time required for redistribution of the isotope. For adenosine to replace dipyridamole, however, it must safely cause coronary hyperemia sufficient to differentiate myocardium perfused by a stenotic artery from that supplied by a normal vessel. These studies suggest that clinically tolerable doses of adenosine cause near-maximal coronary hyperemia in most, but not all, patients. Although the importance of obtaining absolutely maximal (as opposed to near-maximal) coronary vasodilation may be insignificant because epicardial coronary stenoses first cause vasodilation of the subendocardium (the layer most sensitive to the vasodilator properties of adenosine), further clinical studies will be needed to define the comparative sensitivity of 20lfl scintigraphy obtained using adenosine or dipyridamole. 35, 36 The second clinical use of adenosine is in measuring coronary flow reserve in the catheterization laboratory. Intracoronary papaverine, the agent most commonly used to measure flow reserve, cannot be given as a continuous infusion (making difficult its use with measurement techniques with poor temporal resolution such as digital subtraction angiographic methods) and can cause ventricular tachycardia.7 Intracoronary adenosine (bolus or infusion) may be more advantageous than papaverine because it can be given as a continuous infusion without resulting in systemic accumulation, it has no important effects on the electrocardiogram at the doses tested, and it has a short half-life that reduces the potential sequelae of any toxicity (for example, heart block). Similarly, the ability to cause prolonged coronary hyperemia using continuous intracoronary infusions of adenosine should enhance many physiological studies of the coronary circulation.
Although the precise role of adenosine in regulating coronary blood flow is not certain, several aspects of its mechanism of action in causing microvascular vasodilation are known and should be considered when the drug is used in diagnostic or therapeutic studies. The myocytes of coronary resistance vessels have an adenosine receptor (A2) on their cell membrane.37 When combined with adenosine, the plasma membrane-bound receptor protein causes an increase in adenylate cyclase activity and a subsequent increase in intracellular cyclic AMP. The receptor activity is inhibited by theophylline-type compounds (that is, methylxanthines), and theophylline has been shown in animals to reduce adenosineinduced hyperemia by 41-101%.38-41 Hence, patients receiving theophylline, caffeine, or other methylxanthines may not develop maximal coronary hyperemia during adenosine infusion.
A second effect of adenosine is presynaptic inhibition of norepinephrine release from sympathetic nerve terminals. Studies by Johannsen et a142 and others have demonstrated that adenosine reduces, but does not fully override, coronary vasoconstriction during neural sympathetic stimulation. Studies of the effect of sympathetic neural stimulation on the coronary circulation (for example, cold pressor test) should take into account the inhibitory effect of adenosine.
Safety
Adenosine has two important potential side effects. Depression of sinoatrial or atrioventricular node function occurs in a dose-dependent fashion in animals and humans. 21 The doses previously reported to cause heart block in humans were far in excess of those given in this study, and many of the patients concomitantly had received other drugs that depress atrioventricular node function (for example, diltiazem and /3-adrenergic receptor antagonists). We observed one episode of 2:1 atrioventricular block (two cycles) during an intravenous infusion (140 gg/kg/min) in one patient who had previously received diltiazem and atenolol. Although the episode was clinically insignificant, more prolonged atrioventricular node block may occur during an intravenous infusion in patients with preexisting conduction system disease or in patients taking dipyridamole. To avoid important heart block, the dose of intravenous infusions should be slowly titrated, and patients should be instructed to discontinue dipyridamole therapy. In addition, significant anemia may decrease adenosine metabolism and intensify or prolong its effect. Unlike papaverine, however, adenosine does not change the QT interval. Consequently, the 0.5% incidence of polymorphous ventricular tachycardia observed after intracoronary papaverine may be avoided by the routine use of adenosine in the measurement of flow reserve.
Intravenous infusions of adenosine can cause a significant fall in arterial blood pressure and a reflexmediated rise in heart rate. Although these minor hemodynamic changes were well tolerated in our patients, significant hypotension may result in patients with an impaired baroreflex (and, hence, reduced reflex tachycardia) or with intravascular volume depletion, or it may result in those treated concomitantly with dipyridamole.
Finally, although these data suggest that adenosine can be safely administered to patients studied in the catheterization laboratory, we studied only 39 patients. Study in a much larger population will be required to fully ascertain the incidence and predisposing factors of any adverse effects. If more widespread use parallels our experience, adenosine should greatly facilitate studies of the coronary circulation of humans.
